Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · IEX Real-Time Price · USD
3.250
-0.080 (-2.40%)
At close: Jul 19, 2024, 4:00 PM
3.170
-0.080 (-2.46%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 6.00, with a low estimate of 5.00 and a high estimate of 7.00. The average target predicts an increase of 84.62% from the current stock price of 3.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for HRTX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +115.38% | Jun 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +53.85% | May 16, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +53.85% | May 8, 2024 |
| Capital One | Capital One | Buy Initiates $6 | Buy | Initiates | $6 | +84.62% | Apr 23, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +53.85% | Apr 11, 2024 |
Financial Forecast
Revenue This Year
150.81M
from 127.04M
Increased by 18.71%
Revenue Next Year
181.48M
from 150.81M
Increased by 20.34%
EPS This Year
-0.11
from -0.80
EPS Next Year
0.01
from -0.11
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 160.9M | 192.1M | 233.6M | 279.4M | 322.0M |
| Avg | 150.8M | 181.5M | 220.9M | 260.2M | 300.3M |
| Low | 140.0M | 171.5M | 208.5M | 241.6M | 272.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.6% | 27.3% | 28.7% | 26.5% | 23.8% |
| Avg | 18.7% | 20.3% | 21.7% | 17.8% | 15.4% |
| Low | 10.2% | 13.7% | 14.9% | 9.4% | 4.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.03 | 0.06 | 0.27 | 0.53 | 0.66 |
| Avg | -0.11 | 0.01 | 0.23 | 0.46 | 0.60 |
| Low | -0.17 | -0.05 | 0.20 | 0.39 | 0.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 2,514.7% | 125.7% | 44.1% |
| Avg | - | - | 2,180.0% | 97.4% | 30.0% |
| Low | - | - | 1,821.6% | 68.6% | 15.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.